Skip to main content

Atea Pharmaceuticals, Inc.

AVIR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001593899

No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding Atea Pharmaceuticals, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of AVIR: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders1311310
Shares57.8M56.8M−1.04M (−1.8%)
Value$278.1M$190.2M−$87.9M (−31.6%)

New holders (16)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to AVIR in Q1 2023
InstitutionSharesValue% of portfolio
Tang Capital Management LLC1,002,582$3.36M0.50%
Stonepine Capital Management, LLC684,508$2.29M0.77%
Dimensional Fund Advisors LP61,639$206.5K0.00%
Point72 Asset Management, L.P.36,682$122.9K0.00%
XTX Topco Ltd32,630$109.3K0.02%
Prelude Capital Management, LLC28,500$95.5K0.01%
Marquette Asset Management, LLC24,865$83.3K0.02%
Teacher Retirement System of Texas23,091$77.0K0.00%
CM Wealth Advisors LLC19,400$64.0K0.01%
Caxton Associates LP16,998$56.9K0.01%
Bank of Montreal14,692$49.2K0.00%
Integrated Wealth Concepts LLC10,140$34.0K0.00%
Simplex Trading, LLC5,617$18.0K0.00%
Covestor Ltd1,012$3.00K0.00%
Northwestern Mutual Wealth Management Co400$1.34K0.00%
Quadrant Capital Group LLC58$1950.00%

Sold out (16)

Institutions that held Atea Pharmaceuticals, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.